Kambo
Kambo (Phyllomedusa bicolor frog secretion; also spelled kambô, sapo, vacina-do-sapo)
Evidence grade varies by use. See the breakdown on the entry. Read how the Atlas grades evidence.
Evidence for the marketed health and "detox" claims is essentially absent. As of 2026 there are no completed controlled clinical trials in humans showing that Kambo treats or cures any disease; the human literature is dominated by laboratory peptide characterization, internet surveys of users' subjective reports, and a growing body of case reports and reviews of harm. Individual peptides (for example dermorphin-class opioids and antimicrobial dermaseptins) are studied as leads for possible future drugs, but that is preclinical chemistry and does not validate applying raw secretion to a burn. By contrast, the harm signal is concrete and published: case reports and systematic reviews document severe hyponatremia and SIADH, seizures, psychosis, acute kidney injury, liver injury, cardiac arrhythmia and sudden cardiac death, esophageal rupture (Boerhaave syndrome) from forceful vomiting, and at least one 2025 report of hyponatremic toxicity progressing to brain death. Deaths temporally linked to Kambo have been reported across multiple countries. The honest reading is grade 1: the proposed benefits rest on theory and testimonial while the controlled human efficacy evidence is missing, and the documented risks are serious.
Reference only. Not medical advice.
| Treatment | Grade | Notes |
|---|---|---|
| Detoxification / general cleanse | 1 of 5 | Vendor and practitioner claim. The purge is a direct peptide effect; no controlled human evidence that toxins or disease agents are cleared. |
| Mood, anxiety, depression | 1 of 5 | Only internet surveys of users' subjective impressions. No completed controlled trials; mental-health use needs a licensed provider, not a frog burn. |
| Pain, chronic illness, Lyme, cancer | 0 of 5 | No clinical trial support. Disease-cure claims are unproven and, in the US, not legally permitted marketing. |
| Acute purge / vomiting effect | 3 of 5 | This effect is real and reproducible, well explained by caerulein/phyllomedusin pharmacology, but it is a hazard, not a therapeutic benefit. |
| Isolated peptides as future drug leads | 1 of 5 | Preclinical only. Studying dermorphin or dermaseptin chemistry does not validate ceremonial use of raw secretion. |
What can go wrong
Serious. Kambo is not a gentle cleanse. The secretion reliably causes violent vomiting, diarrhea, facial and throat swelling, racing heart, sharp blood-pressure changes, dizziness and fainting. Documented severe outcomes include life-threatening low blood sodium (hyponatremia) and SIADH, often worsened when people drink large volumes of water during ceremony, as well as seizures, psychosis, acute kidney and liver injury, cardiac arrhythmia, sudden cardiac death, and esophageal rupture from forceful vomiting. A 2025 case report describes brain death following Kambo-related hyponatremia. Multiple deaths in different countries have been reported in connection with its use. Risk is higher for people with heart conditions, low blood pressure, epilepsy, kidney or liver disease, eating-disorder history, pregnancy, or who are taking medications, and the "drink lots of water" instruction common in ceremonies can itself precipitate fatal hyponatremia. There is no antidote and no standardized dosing.
This is something to take to a clinician. The Atlas can tell you what is known about kambo in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Kambo is the dried defensive secretion of the Amazonian giant monkey frog, Phyllomedusa bicolor, applied to small burns opened on the skin. Among Panoan-speaking peoples of the Brazil/Peru border such as the Matsés, Katukina, Marubo and Yawanawá, it is foremost a hunting medicine and strengthening cleanse, used to drive off "panema," a state of bad luck and heaviness, and to sharpen a hunter before the chase. In global wellness markets it has been rebranded as a "frog detox" that sellers say clears toxins and treats conditions from anxiety to cancer. Those curative claims are vendor and practitioner statements, not established facts. The secretion's peptides do produce a real and predictable effect, intense vomiting, purging, flushing and cardiovascular changes, but that violent reaction is a hazard rather than proof of healing. As of 2026 there are no completed controlled human trials supporting the health claims, while published case reports document hyponatremia and SIADH, seizures, psychosis, organ injury, cardiac events, esophageal rupture and deaths across several countries. Regulators have responded: Australia classified Kambo as a Schedule 10 prohibited substance in 2021, and Brazil's ANVISA prohibited its sale and marketing in 2004. Enel lists Kambo to document its Indigenous lineage honestly while flagging that the marketed benefits are unproven and the risks are severe.
Burn-applied frog secretion from an Amazonian hunting ritual, now marketed as a "detox," whose violent purge has produced documented deaths and almost no clinical evidence for its health claims.
How it is supposed to work
Established pharmacology: the secretion is a concentrated mix of bioactive peptides, and several of their actions are well characterized in laboratory and animal work. Phyllocaerulein (caerulein) and phyllomedusin act on gut and gallbladder receptors and drive the intense vomiting, salivation, defecation and gut motility that define the experience; sauvagine is a potent corticotropin-releasing-factor agonist and vasodilator that can drop blood pressure and flush the skin; dermorphin and deltorphin are extremely potent opioid-receptor peptides; phyllokinin lowers blood pressure. The acute reaction (facial swelling, racing heart, dizziness, fainting, hard purging) is a real, reproducible effect of these compounds. Proposed and marketed mechanism: practitioners and sellers describe Kambo as a whole-body "detox" that they say clears toxins, resets the immune system and treats conditions from anxiety and depression to chronic pain, addiction, Lyme disease, infertility and cancer. That detox-and-cure framing is a vendor and practitioner claim, not an established mechanism. The dramatic purge is sometimes presented by sellers as proof of "toxins leaving," but vomiting and electrolyte loss are direct peptide effects and are not evidence that disease-causing substances are being removed.
What people get wrong
Often saidThe intense vomiting proves Kambo is flushing toxins out of your body.
ActuallyThe vomiting and purging are direct effects of peptides like caerulein and phyllomedusin acting on the gut. There is no controlled evidence that any disease-causing toxin is being removed.
Often saidIt's a natural frog medicine, so it's safe.
ActuallyNatural does not mean safe. Published case reports tie Kambo to life-threatening low blood sodium, seizures, cardiac events, esophageal rupture and deaths, and Australia classifies it among its most dangerous prohibited substances.
Who profits, and who pushes back
Commercial Kambo practitioner / 'frog medicine' provider
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Providers describe Kambo as a powerful natural detox and reset that they say clears toxins, lifts mood and strengthens the body; these are practitioner claims, not established clinical findings.
Emergency and forensic physicians (case-report and review authors)
Clinicians report hyponatremia, SIADH, seizures, cardiac arrest, esophageal rupture and death linked to Kambo and argue the practice is dangerous and inadequately regulated.
Therapeutic Goods Administration (Australia)
The TGA assessed Kambo as a danger to human health and prohibited its supply and use, placing it in Schedule 10.
Yawanawá / Indigenous leaders
Some Indigenous leaders have publicly warned against non-Indigenous practitioners administering Kambo without community authorization, raising sovereignty and consent concerns.
Where the research comes from
Most of the published research on this comes from one place. 90% of it is from Brazil / Peru Amazon (Indigenous origin). Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| Brazil / Peru Amazon (Indigenous origin) | 90% |
| Brazil (urban) & Latin America | 70% |
| North America | 60% |
| Western Europe | 55% |
| Australia (now prohibited) | 40% |
How we got here
Kambo originates with Panoan-speaking peoples of the southwestern Amazon along the present Brazil/Peru border, among them the Matsés (Mayoruna), Katukina, Marubo, Yawanawá, Kaxinawá and Amahuaca. The medicine is the defensive skin secretion of the giant monkey frog or giant leaf frog, Phyllomedusa bicolor, applied to small superficial burns opened on the skin so the peptides enter through the lymphatic and dermal tissue. In these traditions it is foremost a hunting medicine, used to drive off "panema," a state of bad luck, heaviness or laziness believed to spoil a hunter, and to sharpen stamina, sight and smell before pursuit. It is also taken as a strengthening cleanse against perceived sickness and fatigue. Written ethnographic description by outsiders dates largely to the twentieth century, but the practice is older oral tradition within these communities and is not a Western invention. Its movement into Brazilian cities and then global wellness circuits is a late-twentieth and twenty-first century development layered on top of that Indigenous root.
The deepest layer of Kambo's history is Indigenous and Amazonian. Panoan-speaking peoples of the southwestern Amazon, including the Matsés (Mayoruna), Katukina, Marubo, Yawanawá, Kaxinawá and Amahuaca, used the giant monkey frog's secretion as hunting medicine and ritual cleanse long before outside documentation. Outside ethnographers and travelers began describing the practice in the twentieth century, and from the mid-twentieth century onward it spread from forest communities into Brazilian towns and cities. Through the 1990s and 2000s it moved further, carried by ayahuasca-adjacent spiritual networks and then by a Western 'plant medicine' and biohacking wellness scene, into Europe, North America and Australia, where lay practitioners began offering paid ceremonies. That commercialization is recent and sits on top of, rather than replacing, the Indigenous tradition. The harm record accumulated alongside the spread: Brazil restricted commercial Kambo in 2004 after concerns about non-traditional use, deaths and severe-event case reports appeared across multiple countries through the 2000s, 2010s and into 2026, and Australia moved to outright prohibition in 2021.
- Pre-20th c.Long-standing use as hunting medicine and cleanse among Panoan Amazonian peoples (Matsés, Katukina, Marubo, Yawanawá and others).
- Mid-20th c.Outside ethnographic documentation; practice begins spreading from forest communities into Brazilian towns and cities.
- 2004Brazil's ANVISA prohibits commercial sale and marketing of Kambo amid concern over non-traditional use.
- 2021Australia's TGA classifies Kambo as a Schedule 10 prohibited substance, banning supply and use from 1 October 2021.
- 2025-2026Continued severe case reports (including a 2025 brain-death report) and further deaths keep Kambo under regulatory and media scrutiny.
How it is understood
A living Indigenous tradition of Panoan Amazonian peoples that has been extracted into a commercial global "frog medicine" industry, raising active questions about consent, benefit-sharing and who may legitimately administer it.
Where scholars disagree
Kambo belongs to living Panoan-speaking Amazonian traditions (Matsés, Katukina, Marubo, Yawanawá, Kaxinawá and others). Its rapid commercialization by non-Indigenous practitioners in global wellness markets raises active questions of consent, benefit-sharing and authority. Some Indigenous leaders, including Yawanawá voices, have publicly warned against outsiders administering Kambo without community authorization. Frog collection and habitat pressure add a conservation and stewardship dimension.
The acute purge is a documented pharmacological effect of the secretion's peptides, but the marketed interpretation of that purge as 'detoxification' that removes disease-causing toxins is a separate, contested mechanistic claim. The reproducible clinical finding (violent vomiting and cardiovascular reaction) and the proposed mechanism (toxin clearance / immune reset) carry very different evidence levels and must be treated as separate claims.
Commercial Kambo practitioners and 'frog medicine' sellers
The intense purging reflects the body expelling toxins, and Kambo thereby detoxifies, resets the immune system and helps treat conditions ranging from mood disorders to chronic illness.
What it rests onPractitioner and vendor testimony plus internet surveys of users' subjective impressions; no completed controlled human trials. This is an attributed proponent claim, not established fact.
Pharmacologists and emergency/forensic clinicians (case-report and review authors)
The vomiting, salivation, gut motility and cardiovascular changes are direct receptor-level effects of peptides such as caerulein, phyllomedusin and sauvagine; they do not demonstrate removal of any disease-causing toxin and are themselves the mechanism of harm.
What it rests onCharacterized peptide pharmacology in laboratory and animal work, plus published case reports and systematic reviews documenting hyponatremia, SIADH, seizures, cardiac events and death.
This disagreement is live. It has not settled.
At a glance
- What it is
- Skin secretion of the Amazonian giant monkey frog, Phyllomedusa bicolor, applied to small skin burns.
- Traditional use
- Panoan-speaking peoples' hunting medicine and cleanse to drive off 'panema' (bad luck/heaviness) and sharpen hunters.
- Evidence level
- grade 1. No completed controlled human trials for any marketed health or 'detox' claim as of 2026.
- Safety
- Serious. Documented hyponatremia/SIADH, seizures, cardiac events, esophageal rupture and deaths across multiple countries.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Kambo. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What people take it for. We have not catalogued the claims made for it.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.